We have studied the effect of tropisetron, a 5-HT 3 
Intrathecal morphine provides good pain relief after orthopaedic surgery of the lower extremities [1] [2] [3] . Unfortunately, the use of spinal morphine, even in small doses, is often associated with unpleasant side effects such as urinary retention, pruritus and nausea and vomiting [4] . Specific 5-HT 3 receptor antagonists are beneficial in attenuating nausea and vomiting induced by chemotherapeutic agents in cancer patients [5] [6] [7] . Recently, two 5-HT 3 antagonists, ondansetron [8] [9] [10] and tropisetron [11] have been introduced for the prevention and treatment of emesis after general anaesthesia.
It is important to consider that 5-HT receptor antagonists may influence pain perception in addition to nausea and vomiting. In the spinal cord, 5-HT is involved in antinociception mechanisms [12, 13] . 5-HT increases nociceptive thresholds and tropisetron has been shown to antagonize 5-HTinduced antinociception, suggesting an important role for 5-HT 3 receptors in modulating spinal nociceptive responses [14] . On the other hand, 5-HT 3 receptor antagonists, including tropisetron, have been found to reduce certain types of pain (chemical and inflammatory) by peripheral 5-HT 3 receptor mechanisms [15, 16] .
The efficacy of 5-HT 3 antagonists for prevention of nausea and vomiting after intrathecal administration of morphine has not been investigated. The present study was designed to see if a prophylactic 5-mg dose of i.v. tropisetron influences the incidence of nausea and vomiting, and the quality of postoperative analgesia in patients undergoing hip or knee operations (arthroplasty or osteotomy) under bupivacaine-morphine spinal anaesthesia.
PATIENTS AND METHODS
The study was approved by the Ethics Committee of Surgical Hospital/Helsinki University Central Hospital, and the patients gave informed consent.
We studied 54 ASA I-III patients, undergoing major orthopaedic hip or knee surgery in this randomized, double-blind study (table I). All patients were premedicated with oral diazepam 5 mg (weight 60 kg or less), 10 mg (61-80 kg) or 15 mg (weight greater than 80 kg). Patients older than 75 yr were given diazepam 5 mg (80 kg or less) or 10 mg (>80kg). The subarachnoid puncture was per- 21 formed in the midline of the L3-4 interspace (25-or 27-gauge needle), with the patient in the lateral position. Preservative-free morphine 0.3 mg was mixed with plain 0.5 % bupivacaine 20 mg (a 15-mg dose was used in two patients in the tropisetron and one patient in the saline group) before injection. The level of analgesia to pinprick 60 min after the injection was recorded.
Within 30 min after subarachnoid injection of bupivacaine with morphine, one of the investigators injected either tropisetron 5 mg (3a-tropanyl-lHindole-3-carboxylic acid ester; Sandoz Ltd, Basel, Switzerland) or an equivalent volume of saline i.v. over 2-3 min using a coded syringe. The syringe was filled with the test solution by a trained nurse, according to a note in a sealed envelope. The investigators were unaware of the agent injected.
Non-invasive arterial pressure (oscillotonometry), ECG, heart rate and Sp Oj were monitored in the operating room and in the postanaesthesia care unit. I.v. fluids (Ringer's acetate, hydroxyethyl starch) and erythrocyte concentrate transfusions were given on an individual basis, according to our clinical routines. Oxygen 2-3 litre min"
1 was delivered via a nasal catheter during surgery. During operation, fentanyl 50 ng i.v. for analgesia and diazepam 2.5-5 mg i.v. for sedation were administered, if required. Pain and the need for medication were assessed on an arbitrary scale: 0 = no pain; 1 = mild pain (opioids not needed); 2 = pain (opioids needed); 3 = severe pain (opioids needed immediately) after operation, for 24 h. Ketoprofen 100 mg orally for mild pain (score 1) or oxycodone 0.1-0.14 mg kg" 1 i.m. for more severe pain was given on request. The patients were confined to bed for 24 h. On the ward, they were allowed to drink and eat light meals.
The occurrence of nausea and vomiting was recorded continuously during the patient's stay in the postanaesthesia care unit and on the ward. Pruritus and micturition problems (need for bladder catheterization) and other observations were noted. Patients were assessed for pain, sedation and headache at 6-h intervals: at 15:00 on the ward (by investigator), at 21:00 (by a trained nurse), at 03:00 (by a trained nurse) and at 09:00 (by investigator) and once more if the 24-h observation period was incomplete at 09:00. For analyses, analgesia requirement and episodes of nausea or vomiting were grouped at 6-h intervals. In the case of persistent vomiting, droperidol 1.25 mg i.m. was given. In the recovery room, metoclopramide 10-20 mg i.v. was given.
Statistical analysis
Sample size was established using a sample size calculation to compare the prevalence of nausea in these patients. For this analysis, we used the prevalence published from similar groups of subjects [17] [18] [19] and set critical error levels at p 1 = 0.25 and a = 0.05.
Statistical significance between the mean values was evaluated using Student's t test and between frequencies using Fisher's exact test. The MannWhitney U test was used for level of spinal analgesia.
RESULTS
The characteristics of the patients and perioperative data in the two groups were comparable (table I) .
Two patients in the saline group and three in the tropisetron group were given ketoprofen. The patients in the tropisetron group and one in the saline group who were given ketoprofen also needed oxycodone (table II) . There were no differences between the groups in the number of patients requiring supplementary oxycodone, the total number of doses or the time from the injection of intrathecal morphine to the first administration of i.m. oxycodone. The number of patients who were completely pain-free (score 0) decreased over time at a similar rate in both groups (table III) .
There was no statistically significant difference between the number of patients in the two groups who became nauseated or vomited during the observation period (table IV). In the tropisetron group, there were 11 patients who had no nausea and seven who had nausea on only one occasion; the respective numbers of patients in the saline group were six and 11 (ns). The total number of episodes of nausea, or vomiting, or both, occurring during 7-18 h from the injection of the test drug was greater in the saline group ( fig. 1 ) (ns). Two patients in the tropisetron and one patient in the saline group needed metoclopramide, and eight patients in the tropisetron and six in the saline group required droperidol. Pruritus and urinary retention occurred in almost the same number of patients in the two groups (table  IV) . No postdural puncture headache or ventilatory frequencies less than 10 b.p.m. were observed.
DISCUSSION
Our data indicate that prophylactic i.v. tropisetron had no observable influence on intrathecal morphine analgesia after major hip and knee surgery. Only a small, non-significant reduction in the number of episodes of nausea could be detected after operation for 7-18 h ( fig. 1) . The timing and dose of the tropisetron administration were based on experience in the prevention of chemotherapy-induced emesis [5] and the relatively long elimination half-life (approximately 8 h) of the drug in man (production information, Sandoz Ltd, Basel, Switzerland). Tropisetron was administered 30 min after intrathecal morphine. However, this may be considered as prophylactic, since intrathecally administered morphine reaches the respiratory centre (which is close to the chemoreceptor trigger zone and vomiting centre) by 60 min [4] .
The incidence of nausea in the present study (59% and 74%) was greater than in two of our recent studies in orthopaedic patients: when bupivacaine spinal anaesthesia without addition of intrathecal morphine was given, the postoperative incidence of nausea was 37.5% [17] and when morphine 0.1 mg 24 h" 1 was added, the incidence was 45% [18] . In a recent study, after intrathecal morphine 0.2 mg, the incidence of nausea was 61 % [19] . Although the causes of postoperative nausea after major orthopaedic surgery are multifactorial (opioids, surgery, transfusions, methylmetacrylate, etc.) it is obvious that the disturbingly high incidence of nausea and vomiting in the present study was caused largely by intrathecally administered morphine.
Probably the most important mechanism by which morphine induces nausea is a direct action on dopamine receptors of the chemoreceptor trigger zone [20] in the area postrema. Emesis-inducing gastrointestinal effects of morphine include decrease in gastric motility and spasms and nonpropulsive contractions of the upper part of the small intestine [21] . There is also a vestibular component in morphine-induced nausea, which may not have played any major role in the present study, as the patients were recumbent in bed for the entire 24-h period. Considering the relatively small dose of intrathecal morphine used (0.3 mg), the blood concentrations of morphine were probably too small to exert systemic effects. Therefore, it may be assumed that morphine migrated slowly to the chemoreceptor trigger zone and provoked nausea by acting directly via stimulation of the zone [22] . Intrathecally distributed morphine may diffuse directly through the ependymal floor of the fourth ventricle, thereby reaching the area postrema. This part of the central nervous system is known to contain large numbers of 5-HT 3 receptors [23, 24] .
It has been suggested that another 5-HT 3 receptor antagonist, ondansetron, may be a useful antiemetic in surgical patients after general anaesthesia [9, 10] . These studies, in addition to experiences from the use of this drug in chemotherapy-induced nausea and vomiting [25] , indicate that the 5-HT 3 antagonist is perhaps more effective in reducing vomiting than in preventing nausea. In contrast, we could not demonstrate such a differential action by a single prophylactic dose of tropisetron.
Side effects such as headache and sedation, which occur in cancer patients during tropisetron treatment [5] , were not observed in our patients.
The lack of significant effect of tropisetron on nausea and vomiting after subarachnoid morphine in the present study is not suggestive of an important role of 5-HT 3 receptor involvement in this particular type of nausea. The nausea associated with cisplatin therapy is at least in part caused by the release of 5-HT from the viscera and activation of 5-HT 3 receptors [7] and it can therefore be attenuated to a clinically significant degree with specific 5-HT 3 antagonists. There are also suggestions that the 5-HT 3 receptor antagonists may act on peripheral receptors found in abdominal visceral afferent neurones [26] , which could explain the poor antiemetic effect of the 5-HT 3 antagonist in the present subarachnoid morphine study. Metoclopramide, one of the rescue antiemetics used in our study, might be better suited for the prevention and treatment of nausea induced by subarachnoid morphine [27] . Metoclopramide increases lower oesophageal sphincter tone and enhances gastric and bowel motility and has antidopaminergic [28] and, in large doses, also an anti-5HT receptor action [29] .
